RenovoCath

Mountain View, Calif. – August 25, 2026 RenovoRx highlighted the publication of pharmacokinetic and pharmacodynamic (PK/PD) data supporting its...

Mountain View, California, U.S. | August 20, 2026 RenovoRx announced that the U.S. Patent and Trademark Office (USPTO) has...

Mountain View, California, USA – April 23, 2026 RenovoRx announced that a pharmacokinetic (PK) and pharmacodynamic (PD) data abstract...

MOUNTAIN VIEW, Calif., November 4, 2025 — RenovoRx, Inc. (NASDAQ: RNXT), a life sciences company pioneering targeted oncology therapies...